Literature DB >> 34249316

Best management of irritable bowel syndrome.

Christopher J Black1,2, Alexander Charles Ford1,2.   

Abstract

Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction which can have a considerable impact on quality of life. Following diagnosis, timely and evidence-based management is vital to the care of patients with IBS, aiming to improve outcomes, and enhance patient satisfaction. Good communication is paramount, and clinicians should provide a clear explanation about the disorder, with a focus on exploring the patient's own beliefs about IBS, and a discussion of any concerns they may have. It should be emphasised that symptoms are often chronic, and that treatment, while aiming to improve symptoms, may not relieve them completely. Initial management should include simple lifestyle and dietary advice, discussion of the possible benefit of some probiotics, and, if this is unsuccessful, patients can be referred to a dietician for consideration of a low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet. Antispasmodics and peppermint oil can be used first-line for the treatment of abdominal pain. If patients fail to respond, central neuromodulators can be used second-line; tricyclic antidepressants should be preferred. Loperamide and laxatives can be used first-line for treating diarrhoea and constipation, respectively. Patients with constipation who fail to respond to laxatives should be offered a trial of linaclotide. For patients with diarrhoea, the 5-hydroxytryptamine-3 receptor agonists alosetron and ramosetron appear to be the most effective second-line drugs. Where these are unavailable, ondansetron is a reasonable alternative. If medical treatment is unsuccessful, patients should be referred for psychological therapy, where available, if they are amenable to this. Cognitive behavioural therapy and gut-directed hypnotherapy are the psychological therapies with the largest evidence base. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  irritable bowel syndrome

Year:  2020        PMID: 34249316      PMCID: PMC8231425          DOI: 10.1136/flgastro-2019-101298

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  95 in total

1.  Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E.

Authors:  Annette Fritscher-Ravens; Theresa Pflaum; Marie Mösinger; Zino Ruchay; Christoph Röcken; Peter J Milla; Melda Das; Martina Böttner; Thilo Wedel; Detlef Schuppan
Journal:  Gastroenterology       Date:  2019-05-15       Impact factor: 22.682

2.  Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials.

Authors:  Changli Zhou; Enfa Zhao; Yuewei Li; Yong Jia; Feng Li
Journal:  Neurogastroenterol Motil       Date:  2018-09-19       Impact factor: 3.598

3.  Food-related gastrointestinal symptoms in the irritable bowel syndrome.

Authors:  M Simrén; A Månsson; A M Langkilde; J Svedlund; H Abrahamsson; U Bengtsson; E S Björnsson
Journal:  Digestion       Date:  2001       Impact factor: 3.216

4.  Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial.

Authors:  Carla E Flik; Wijnand Laan; Nicolaas P A Zuithoff; Yanda R van Rood; André J P M Smout; Bas L A M Weusten; Peter J Whorwell; Niek J de Wit
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-11-23

5.  Medical and lay views of irritable bowel syndrome.

Authors:  M Dixon-Woods; S Critchley
Journal:  Fam Pract       Date:  2000-04       Impact factor: 2.267

6.  An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.

Authors:  Roberto Lewis-Fernández; Peter Lam; Susan Lucak; Hanga Galfalvy; Elizabeth Jackson; Jane Fried; Melissa Rosario; Ana Alicia de la Cruz; Arturo Sánchez-Lacay; Samantha Díaz; Franklin Schneier
Journal:  J Clin Psychopharmacol       Date:  2016-12       Impact factor: 3.153

7.  General practitioners' perceptions of irritable bowel syndrome: a Q-methodological study.

Authors:  Stephen Bradley; Sarah Alderson; Alexander C Ford; Robbie Foy
Journal:  Fam Pract       Date:  2018-01-16       Impact factor: 2.267

8.  The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects.

Authors:  Anna Kassinen; Lotta Krogius-Kurikka; Harri Mäkivuokko; Teemu Rinttilä; Lars Paulin; Jukka Corander; Erja Malinen; Juha Apajalahti; Airi Palva
Journal:  Gastroenterology       Date:  2007-04-14       Impact factor: 22.682

Review 9.  Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.

Authors:  Patrick Welsch; Nurcan Üçeyler; Petra Klose; Brian Walitt; Winfried Häuser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-28

Review 10.  Review article: the economic impact of the irritable bowel syndrome.

Authors:  C Canavan; J West; T Card
Journal:  Aliment Pharmacol Ther       Date:  2014-09-09       Impact factor: 8.171

View more
  6 in total

Review 1.  Microscopic colitis in older adults: impact, diagnosis, and management.

Authors:  Istvan Fedor; Eva Zold; Zsolt Barta
Journal:  Ther Adv Chronic Dis       Date:  2022-07-05       Impact factor: 4.970

2.  Increased prescriptions for irritable bowel syndrome after the 2018 Japan Floods: a longitudinal analysis based on the Japanese National Database of Health Insurance Claims and Specific Health Checkups.

Authors:  Yuji Okazaki; Shuhei Yoshida; Saori Kashima; Daisuke Miyamori; Masatoshi Matsumoto
Journal:  BMC Gastroenterol       Date:  2022-05-26       Impact factor: 2.847

Review 3.  Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.

Authors:  Emily V Wechsler; Eric D Shah
Journal:  Drugs       Date:  2021-11-02       Impact factor: 9.546

4.  Investigation the Effectiveness of Duloxetine in Quality of Life and Symptoms of Patients with Irritable Bowel Syndrome.

Authors:  Razieh Salehian; Marjan Mokhtare; Atefeh Ghanbari Jolfaei; Rouhallah Noorian
Journal:  Adv Biomed Res       Date:  2021-06-28

5.  Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with Constipation-Randomized Case-Control Study.

Authors:  Oana-Bogdana Bărboi; Ioan Chirilă; Irina Ciortescu; Carmen Anton; Vasile-Liviu Drug
Journal:  J Clin Med       Date:  2022-04-17       Impact factor: 4.964

Review 6.  Heart Rate Variability-An Index of the Efficacy of Complementary Therapies in Irritable Bowel Syndrome: A Systematic Review.

Authors:  Magdalena Mróz; Marcin Czub; Anna Brytek-Matera
Journal:  Nutrients       Date:  2022-08-22       Impact factor: 6.706

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.